Rx-Only Pseudoephedrine Legislation Spreads To More States
This article was originally published in The Tan Sheet
Executive Summary
Hawaii, Indiana, Kentucky and Virginia join the list of states considering legislation to require a prescription for all drugs containing pseudoephedrine.
You may also be interested in...
Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
In Brief
Valeant acquires iNova, closes Afexa deal; CRN says FDA’s proposed rule on gifts “goes too far”; Kentucky bill would strengthen PSE limits; and more OTC drug and nutritional product market news In Brief